2020 American Transplant Congress
Low Mycophenolic Acid Levels are Associated with More Inflammation on 1 Year Protocol Biopsies and Lower Graft Survival in Kidney Transplant Recipients
Mayo Clinic Arizona, Phoenix, AZ
*Purpose: Data is limited on the association of Mycophenolic Acid (MPA) concentration on protocol kidney transplant biopsies. Our aim is to compare clinical outcomes and…2019 American Transplant Congress
Polymorphisms in Mycophenolate Mofetil Glucuronidation Gene Are Associated with Leukopenia and Decreased CLAD-Free Survival
UCSF Medical Center, San Francisco, CA
*Purpose: Lung transplant recipients vary in their tolerance of the immunosuppressant mycophenolate mofetil (MMF). Single nucleotide polymorphisms (SNPs) in UDP-glucuronosyltransferase 2B7 (UGT2B7) increase conversion of…2019 American Transplant Congress
Evaluation of Mycophenolate Mofetil Exposure in Renal Transplant Recipients
*Purpose: Mycophenolate mofetil (MMF) is the most commonly prescribed immunosuppressant following transplantation in the United States. However, the occurrence of MMF therapy-related adverse events including…2019 American Transplant Congress
Post-Transplant Cancer and Graft Failure in Kidney Transplant Recipients
Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: As the long-term patient survival and graft survival rate are gradually increasing in kidney transplant (KT) recipients, the importance of cancer occurrence and proper…2019 American Transplant Congress
Mycophenolate Mofetil versus Azathioprine in Kidney Transplant Recipients on Steroid-Free Low-Dose Cyclosporine Immunosuppression: The ATHENA Trial
*Purpose: Registration trials using old sandimmune formulation of cyclosporine (CsA) led to the general idea that Mycophenolate Mofetil (MMF) prevents acute cellular rejection (ACR) more…2018 American Transplant Congress
Mycophenolate Monotherapy is Safe and Effective in HLA-Matched Kidney Transplant Recipients
Purpose: The ideal minimizing strategy for maintenance immunosuppression in HLA-matched kidney transplant recipients (KTR) is unknown. We hypothesized that mycophenolate (MPA) monotherapy is a safe…2018 American Transplant Congress
Mycophenolic Acid Reduces BK Polyomavirus Replication in an In Vitro Model of Renal Tubular Epithelial Cells Infection
Background. BK virus (BKV) nephropathy is an important cause of allograft failure after kidney transplant. Immunosuppression is a recognized risk factor for BKV replication but…2018 American Transplant Congress
Outcomes of Pregnancies in Female Liver Transplant Recipients
The purpose of this study is to describe 544 pregnancies in 278 liver transplant recipients reporting to the Transplant Pregnancy Registry International (TPR) from 1991…2018 American Transplant Congress
Evaluation of MPA Dose on Development of DSA Following Pancreas Transplant
The relationship between mycophenolate (MPA) dose and the development of donor specific antibody (DSA) following pancreas transplant has not been elucidated. This study evaluates the…2018 American Transplant Congress
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation
Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…
American Transplant Congress abstracts